Kymera Therapeutics (KYMR) Free Cash Flow (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Free Cash Flow of -$89.3 million for Q1 2026, down 12.13% year-over-year from -$101.6 million in Q1 2025, and down 23.02% quarter-over-quarter from -$72.6 million in Q4 2025.
Kymera Therapeutics (KYMR) Free Cash Flow (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Free Cash Flow for 8 consecutive years, with -$89.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 12.13% year-over-year to -$89.3 million; the TTM figure through Mar 2026 stood at -$249.7 million (down 4.06% YoY), while the FY2025 annual figure was -$240.1 million, down 15.78% from the prior year.
- Free Cash Flow slipped to -$89.3 million in Q1 2026 per KYMR's latest filing, from -$72.6 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $9.0 million in Q4 2023 and bottomed at -$89.3 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$46.6 million across 5 years, with a median of -$47.0 million in 2024.
- Annual changes were most pronounced in 2023 — Free Cash Flow soared 123.52% — and 2024, when it plunged 800.47%.
- Kymera Therapeutics' Free Cash Flow stood at -$38.1 million in 2022, then jumped by 123.52% to $9.0 million in 2023, then slumped by 800.47% to -$62.7 million in 2024, then declined by 15.7% to -$72.6 million in 2025, then fell by 23.02% to -$89.3 million in 2026.
- Business Quant data shows KYMR's Free Cash Flow at -$89.3 million in Q1 2026, -$72.6 million in Q4 2025, and -$27.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | -51.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -51.90 Mn |
| Jun 30, 2026 | -51.90 Mn |
| Mar 31, 2026 | -89.27 Mn |
| Mar 31, 2026 | -89.27 Mn |
| Dec 31, 2025 | -72.57 Mn |
| Dec 31, 2025 | -72.57 Mn |
| Sep 30, 2025 | -27.29 Mn |
| Sep 30, 2025 | -27.29 Mn |
| Jun 30, 2025 | -60.58 Mn |
| Jun 30, 2025 | -60.58 Mn |
| Mar 31, 2025 | -79.62 Mn |
| Mar 31, 2025 | -79.62 Mn |
| Dec 31, 2024 | -62.72 Mn |
| Dec 31, 2024 | -62.72 Mn |
| Sep 30, 2024 | -50.00 Mn |
| Sep 30, 2024 | -50.00 Mn |
| Jun 30, 2024 | -47.63 Mn |
| Jun 30, 2024 | -47.63 Mn |
| Mar 31, 2024 | -46.99 Mn |
| Mar 31, 2024 | -46.99 Mn |